The biotechnology company Vytrus Biotech, a benchmark in the development of active ingredients derived from plant stem cells for the cosmetic industry, has presented a preliminary report of results for the 2025 fiscal year that marks a milestone in its financial trajectory. According to the report submitted to the market, the Catalan firm has achieved a turnover of 8.37 million euros, representing spectacular growth of 66% compared to the income obtained the previous yearBeyond the notable increase in turnover, the most outstanding figure of the year is the company's ability to scale its business model. Vytrus has managed to grow its profits at a much faster rate than its sales. The EBITDA (earnings before interest, taxes, depreciation, and amortization) has stood at 4.16 million euros, representing an increase of 106% compared to 2024
This optimization of profitability has allowed the EBITDA margin to be raised to 49.6%, compared to the 40% recorded in the previous period. This financial success is attributed to a combination of factors: rigorous management of operating costs, the maturation of its product catalog, and the successful launch of new innovations, such as its 'Exopeptides' technology, which has been well-received in the premium market.
Vytrus Biotech's growth during 2025 has been balanced and global, with a presence already in 51 countries. Nevertheless, the dynamism of certain regions has been decisive:
-
Asia-Pacific: has consolidated itself as the engine of growth with a sales increase of 144%, driven mainly by excellent performance in the Indian market.
-
Europe: the European Union has shown great solidity with a growth of 63%.
-
United States: despite being a highly competitive market, sales have advanced by 39%.
-
Rest of the world: other emerging markets have contributed a joint growth of 80%.
To sustain this pace of expansion, the company has initiated an investment phase in key infrastructures. Vytrus is preparing for the move to a new production and logistics plant in Terrassa, which will have a surface area of 1,600 m². This center will allow it to multiply its production capacity to respond to the global demand foreseen in the coming years
Financial support has been another pillar of the exercise, highlighting the obtaining of a loan of 1.5 million euros from the Institut Català de Finances (ICF). With these resources and the current results, Vytrus Biotech is firmly heading towards its Strategic Plan 2024-2027, whose ultimate goal is to achieve a turnover of 12 million euros, consolidating itself as an undisputed leader in plant biotechnology applied to dermocosmetics.